Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036341 (
schizophrenia
)
60,220
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The decrease of glutamic acid decarboxylase (GAD) has been reported as an important neurochemical alteration of the inhibitory GABAergic interneurons in
schizophrenia
. To our knowledge no studies have investigated the genetic variants influencing GAD expression. To search for markers contributing to the genetic susceptibility of
schizophrenia
, we typed two polymorphisms by polymerase chain reaction-restriction fragment length polymorphism in both
GAD1
and GAD2 genes in 112 triad families and 46 case-controls. We used the Transmission Disequilibrium Test to perform the qualitative family-based analyses and found negative results (
GAD1
, chi2 = 0.273, 1 degree of freedom, P = 0.60; GAD2, chi2 = 0, 1 degree of freedom, P = 1). In addition there were no associations with
GAD1
and GAD2 and quantitative measures of suicide behaviour in this sample. Although our results are negative, this was the first study to investigate GAD genes in
schizophrenia
, and further studies of these genes, particularly with
schizophrenia
subtypes, may prove valuable.
...
PMID:Polymorphisms in glutamate decarboxylase genes: analysis in schizophrenia. 1509 14
Postmortem brain studies have shown deficits in the cortical gamma-aminobutyric acid (GABA) system in schizophrenic individuals. Expression studies have shown a decrease in the major GABA-synthesizing enzyme (glutamic acid decarboxylase (GAD67) mRNA levels in neurons in dorsolateral prefrontal cortex in schizophrenics relative to controls. In the present study, SNPs in and around the
GAD1
gene, which encodes the protein GAD67, were tested on a rare, severely ill group of children and adolescents with childhood-onset
schizophrenia
(COS) (n=72), in a family-based association analysis. Compared to adult-onset samples, the COS sample has evidence for more salient familial, and perhaps genetic, risk factors for
schizophrenia
, as well as evidence for frontal cortical hypofunction, and greater decline in cortical gray matter volume on anatomic brain MRI scans during adolescence. We performed family-based TDT and haplotype association analyses of the clinical phenotype, as well as association analyses with endophenotypes using the QTDT program. Three adjacent SNPs in the 5' upstream region of
GAD1
showed a positive pairwise association with illness in these families (P=0.022-0.057). Significant transmission distortion of 4-SNP haplotypes was also observed (P=0.003-0.008). Quantitative trait TDT analyses showed an intriguing association between several SNPs and increased rate of frontal gray matter loss. These observations, when taken together with the positive results reported recently in two independent adult-onset
schizophrenia
pedigree samples, suggest that the gene encoding GAD67 may be a common risk factor for
schizophrenia
.
...
PMID:GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. 1550 39
Neurodevelopmental models of
schizophrenia
that identify longitudinal precursors of illness have been of great heuristic importance focusing most etiologic research over the past two decades. These models have varied considerably with respect to specificity and timing of hypothesized genetic and environmental 'hits', but have largely focused on insults to prenatal brain development. With heritability around 80%, nongenetic factors impairing development must also be part of the model, and any model must also account for the wide range of age of onset. In recent years, longitudinal brain imaging studies of both early and adult (to distinguish from late ie elderly) onset populations indicate that progressive brain changes are more dynamic than previously thought, with gray matter volume loss particularly striking in adolescence and appearing to be an exaggeration of the normal developmental pattern. This supports an extended time period of abnormal neurodevelopment in
schizophrenia
in addition to earlier 'lesions'. Many subtle cognitive, motor, and behavioral deviations are seen years before illness onset, and these are more prominent in early onset cases. Moreover,
schizophrenia
susceptibility genes and chromosomal abnormalities, particularly as examined for early onset populations (ie
GAD1
, 22q11DS), are associated with premorbid neurodevelopmental abnormalities. Several candidate genes for
schizophrenia
(eg dysbindin) are associated with lower cognitive abilities in both schizophrenic and other pediatric populations more generally. Postmortem human brain and developmental animal studies document multiple and diverse effects of developmental genes (including
schizophrenia
susceptibility genes), at sequential stages of brain development. These may underlie the broad array of premorbid cognitive and behavioral abnormalities seen in
schizophrenia
, and neurodevelopmental disorders more generally. Increased specificity for the most relevant environmental risk factors such as exposure to prenatal infection, and their interaction with susceptibility genes and/or action through phase-specific altered gene expression now both strengthen and modify the neurodevelopmental theory of
schizophrenia
.
...
PMID:The neurodevelopmental model of schizophrenia: update 2005. 1570 48
Recent evidence from postmortem studies suggests that
GAD1
encoding the gamma-aminobutyric acid (GABA) synthetic enzyme GAD67 is a functional candidate susceptibility gene for both bipolar affective disorder (BPAD) and
schizophrenia
. Previous studies suggest linkage between D2S326 near
GAD1
and BPAD. We systematically screened
GAD1
exons, flanking intronic sequences, and the promoter sequence for polymorphisms in 16 BPAD patients and five controls from Denmark. We identified eight single nucleotide polymorphisms (SNPs) including two in the promoter sequence. An association study of SNPs covering
GAD1
was performed in a Danish sample of 82 BPAD subjects and 120 controls and in a Scottish sample of 197 individuals with
schizophrenia
, 200 BPAD subjects and 199 controls. Linkage disequilibrium (LD) and haplotype frequencies were estimated from genotype data from eight SNPs. Strong pairwise LD was observed among all pairs of neighboring markers. In the Danish sample, we found weak association between BPAD and two promoter SNPs spaced 1 kb apart. Furthermore, one, two, and three loci haplotype analysis showed weak association with BPAD in the Danish sample. The results from the association studies indicate that promoter variants are of importance for the Danish BPAD cases and we cannot reject the hypothesis of
GAD1
as a functional candidate gene for BPAD. No association was observed between BPAD or
schizophrenia
and any of the investigated SNPs in the Scottish sample set. Thus the results obtained from the Scottish sample suggest that the
GAD1
gene variants do not play a major role in the predisposition to
schizophrenia
.
...
PMID:Mutational screening and association study of glutamate decarboxylase 1 as a candidate susceptibility gene for bipolar affective disorder and schizophrenia. 1580 82
Neurodevelopmental changes may underlie the brain dysfunction seen in
schizophrenia
. While advances have been made in our understanding of the genetics of
schizophrenia
, little is known about how non-genetic factors interact with genes for
schizophrenia
. The present analysis of genes potentially associated with
schizophrenia
is based on the observation that hypoxia prevails in the embryonic and fetal brain, and that interactions between neuronal genes, molecular regulators of hypoxia, such as hypoxia-inducible factor 1 (HIF-1), and intrinsic hypoxia occur in the developing brain and may create the conditions for complex changes in neurodevelopment. Consequently, we searched the literature for currently hypothesized candidate genes for susceptibility to
schizophrenia
that may be subject to ischemia-hypoxia regulation and/or associated with vascular expression. Genes were considered when at least two independent reports of a significant association with
schizophrenia
had appeared in the literature. The analysis showed that more than 50% of these genes, particularly AKT1, BDNF, CAPON, CCKAR, CHRNA7, CNR1, COMT, DNTBP1,
GAD1
, GRM3, IL10, MLC1, NOTCH4, NRG1, NR4A2/NURR1, PRODH, RELN, RGS4, RTN4/NOGO and TNF, are subject to regulation by hypoxia and/or are expressed in the vasculature. Future studies of genes proposed as candidates for susceptibility to
schizophrenia
should include their possible regulation by physiological or pathological hypoxia during development as well as their potential role in cerebral vascular function.
...
PMID:Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia. 1663 32
The 67 and 65 kDa isoforms of glutamic acid decarboxylase, the key enzymes for GABA biosynthesis, are expressed at altered levels in postmortem brain of subjects diagnosed with
schizophrenia
and related disorders, including autism and bipolar illness. The predominant finding is a decrease in GAD67 mRNA levels, affecting multiple brain regions, including prefrontal and temporal cortex. Postmortem studies, in conjunction with animal models, identified several mechanisms that contribute to the dysregulation of GAD67 in cerebral cortex. These include disordered connectivity formation during development, abnormal expression of Reelin and neural cell adhesion molecule (NCAM) glycoproteins, defects in neurotrophin signaling and alterations in dopaminergic and glutamatergic neurotransmission. These mechanisms are likely to operate in conjunction with genetic risk factors for psychosis, including sequence polymorphisms residing in the promoter of
GAD1
(2q31), the gene encoding GAD67. We propose an integrative model, with multiple molecular and cellular mechanisms contributing to transcriptional dysregulation of GAD67 and cortical dysfunction in psychosis.
...
PMID:Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. 1675 10
Postmortem studies regarding
schizophrenia
revealed altered expression of genes related to gamma-amino butyric acid neurotransmission system. One of the most consistent findings is the reduced level of 67 kDa glutamic acid decarboxylase isoform (GAD(67)). Moreover, several studies reported positive associations between the GAD(67) gene (
GAD1
) and
schizophrenia
. These reasons, motivated us to carry out replication study regarding association between
GAD1
(fourteen tagging SNPs) and
schizophrenia
in Japanese population (562 schizophrenic patients and 470 controls). However we couldn't confirm significant association that had been previously reported. Considering size of our sample and strategy that corresponds well with the approaches used in gene-based association analysis, our conclusion is that
GAD1
does not play a major role in
schizophrenia
in Japanese population.
...
PMID:No association between the glutamate decarboxylase 67 gene (GAD1) and schizophrenia in the Japanese population. 1730 89
Several studies have suggested the dysfunction of the GABAergic system as a risk factor in the pathogenesis of
schizophrenia
. In the present study, case-control association analysis was conducted in four GABAergic genes: two glutamic acid decarboxylase genes (
GAD1
and GAD2), a GABA(A) receptor subunit beta2 gene (GABRB2) and a GABA(B) receptor 1 gene (GABBR1). Using a universal DNA microarray procedure we genotyped a total of 20 SNPs on the above four genes in a study involving 292 patients and 286 controls of Chinese descent. Statistically significant differences were observed in the allelic frequencies of the rs187269C/T polymorphism in the GABRB2 gene (P=0.0450, chi(2)=12.40, OR=1.65) and the -292A/C polymorphism in the
GAD1
gene (P=0.0450, chi(2)=14.64 OR=1.77). In addition, using an electrophoretic mobility shift assay (EMSA), we discovered differences in the U251 nuclear protein binding to oligonucleotides representing the -292 SNP on the
GAD1
gene, which suggests that the -292C allele has reduced transcription factor binding efficiency compared with the 292A allele. Using the multifactor-dimensionality reduction method (MDR), we found that the interactions among the rs187269C/T polymorphism in the GABRB2 gene, the -243A/G polymorphism in the GAD2 gene and the 27379C/T and 661C/T polymorphisms in the
GAD1
gene revealed a significant association with
schizophrenia
(P<0.001). These findings suggest that the GABRB2 and
GAD1
genes alone and the combined effects of the polymorphisms in the four GABAergic system genes may confer susceptibility to the development of
schizophrenia
in the Chinese population.
...
PMID:Systematic study of association of four GABAergic genes: glutamic acid decarboxylase 1 gene, glutamic acid decarboxylase 2 gene, GABA(B) receptor 1 gene and GABA(A) receptor subunit beta2 gene, with schizophrenia using a universal DNA microarray. 1741 63
Dysfunction of prefrontal cortex in
schizophrenia
includes changes in GABAergic mRNAs, including decreased expression of
GAD1
, encoding the 67 kDa glutamate decarboxylase (GAD67) GABA synthesis enzyme. The underlying molecular mechanisms remain unclear. Alterations in DNA methylation as an epigenetic regulator of gene expression are thought to play a role but this hypothesis is difficult to test because no techniques are available to extract DNA from
GAD1
expressing neurons efficiently from human postmortem brain. Here, we present an alternative approach that is based on immunoprecipitation of mononucleosomes with anti-methyl-histone antibodies differentiating between sites of potential gene expression as opposed to repressive or silenced chromatin. Methylation patterns of CpG dinucleotides at the
GAD1
proximal promoter and intron 2 were determined for each of the two chromatin fractions separately, using a case-control design for 14
schizophrenia
subjects affected by a decrease in prefrontal
GAD1
mRNA levels. In controls, the methylation frequencies at CpG dinucleotides, while overall higher in repressive as compared to open chromatin, did not exceed 5% at the proximal
GAD1
promoter and 30% within intron 2. Subjects with
schizophrenia
showed a significant, on average 8-fold deficit in repressive chromatin-associated DNA methylation at the promoter. These results suggest that chromatin remodeling mechanisms are involved in dysregulated GABAergic gene expression in
schizophrenia
.
...
PMID:GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. 1772 39
Cortical GABAergic dysfunction has been implicated as a key component of the pathophysiology of
schizophrenia
and decreased expression of the gamma-aminobutyric acid (GABA) synthetic enzyme glutamic acid decarboxylase 67 (GAD(67)), encoded by
GAD1
, is found in schizophrenic post-mortem brain. We report evidence of distorted transmission of single-nucleotide polymorphism (SNP) alleles in two independent
schizophrenia
family-based samples. In both samples, allelic association was dependent on the gender of the affected offspring, and in the Clinical Brain Disorders Branch/National Institute of Mental Health (CBDB/NIMH) sample it was also dependent on catechol-O-methyltransferase (COMT) Val158Met genotype. Quantitative transmission disequilibrium test analyses revealed that variation in
GAD1
influenced multiple domains of cognition, including declarative memory, attention and working memory. A 5' flanking SNP affecting cognition in the families was also associated in unrelated healthy individuals with inefficient BOLD functional magnetic resonance imaging activation of dorsal prefrontal cortex (PFC) during a working memory task, a physiologic phenotype associated with
schizophrenia
and altered cortical inhibition. In addition, a SNP in the 5' untranslated (and predicted promoter) region that also influenced cognition was associated with decreased expression of
GAD1
mRNA in the PFC of schizophrenic brain. Finally, we observed evidence of statistical epistasis between two SNPs in COMT and SNPs in
GAD1
, suggesting a potential biological synergism leading to increased risk. These coincident results implicate
GAD1
in the etiology of
schizophrenia
and suggest that the mechanism involves altered cortical GABA inhibitory activity, perhaps modulated by dopaminergic function.
...
PMID:Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. 1776 49
1
2
3
4
5
Next >>